Table 1.
Patients’ Characteristics at Baseline.
| Active Cancer | Active Cancer | ||||||
|---|---|---|---|---|---|---|---|
| Baseline, % | Total N = 2056 | With, N = 174 | Without, N = 1882 | Baseline, % | Total N = 2056 | With, N = 174 | Without, N = 1882 |
| Age, years, mean (SD) | 59.8 (16.8) | 59.1 (17.0) | 67.9 (11.9)a | ||||
| Male | 52.9 | 52.7 | 55.8 | Comorbidities | |||
| BMI, mean (SD) | 27.8 (5.3) | 27.9 (5.3) | 26.4 (5.1) | Active cancer | 84.6 | 100.0 | 0.0 |
| Highest graduation | Hypertension | 39.7 | 39.5 | 41.4 | |||
| Primary school | 26.7 | 25.6 | 38.5 | Congestive heart failure | 2.8 | 2.8 | 3.5 |
| Secondary school | 47.7 | 48.0 | 44.3 | Vascular disease | 5.5 | 5.3 | 7.5 |
| Above | 20.9 | 21.4 | 15.5 | Dyslipidemia | 17.5 | 17.5 | 17.8 |
| Marital status | Diabetes | 9.7 | 9.5 | 12.6 | |||
| Single | 13.8 | 15.6 | 6.3 | Chronic venous insufficiency | 16.6 | 17.1 | 10.9 |
| Married/living as married | 65.7 | 64.8 | 75.3 | Renal disease | 6 | 5.8 | 8.7 |
| Separated/divorced | 5.7 | 6.0 | 3.5 | Liver disease | 2.6 | 1.9 | 9.8a |
| Widowed | 10.8 | 10.5 | 13.2 | Chronic respiratory disease | 7.6 | 7.7 | 6.3 |
| Other | 1.1 | 1.1 | 1.2 | Arthritis | 8.8 | 9.1 | 5.2 |
| Country | Bone fracture/soft-tissue trauma | 12.4 | 13.0 | 6.3a | |||
| France | 11.6 | 11.1 | 16.7a | Lower extremity paralysis | 1.2 | 1.2 | 1.2 |
| DACH | 30.3 | 31.8 | 14.4 | Thrombophilia | 7.5 | 7.9 | 4.0 |
| Italy | 28.0 | 25.7 | 52.3a | Cardiovascular disease | 12.9 | 12.6 | 15.5 |
| Spain | 12.0 | 12.4 | 6.9 | ||||
| The United Kingdom | 18.2 | 19.0 | 9.8 | Risk factors (within past 3 months or ongoing) | |||
| Previous clinical event (within 3 years prior to enrollment) | Alcohol use | 18.4 | 19.4 | 7.5a | |||
| Myocardial infarction | 3.1 | 2.9 | 4.6 | Smoking history | 30.3 | 30.5 | 27.8 |
| Coronary artery disease | 3.8 | 3.6 | 5.8 | Prolong immobilization | 15.9 | 16.2 | 12.1a |
| Percutaneous coronary intervention | 1.8 | 1.7 | 2.9 | >5 days in bed | 9.9 | 9.6 | 13.9 |
| Atrial fibrillation | 2.6 | 2.5 | 4.1 | Varicose veins | 22.1 | 22.8 | 14.9a |
| Transient ischemic attack | 2 | 2.0 | 2.3 | Major surgery or trauma | 14.4 | 14.1 | 17.2a |
| Stroke | 2.2 | 2.2 | 2.3 | DVT symptoms present | |||
| Bleeding event | 3.6 | 3.3 | 6.9 | Pain | 82.8 | 83.9 | 71.3 |
| Clinical factors | Discoloration | 16.2 | 16.2 | 16.1 | |||
| Previous VTE event | 25.7 | 26.8 | 13.8a | Calf tenderness | 29.4 | 29.6 | 27.0 |
| Proximal | 71.3 | 71.2 | 71.8 | Swelling | 73.4 | 73.2 | 75.3 |
| Provoked | 27.5 | 27.4 | 27.8 | Collateral superficial veins | 7.3 | 7.2 | 8.1 |
| Baseline treatment | Other | 5.8 | 5.5 | 9.2 | |||
| Use of heparin | 64.9 | 83.9 | 63.1a | ||||
| Use of VKA | 42.7 | 17.8 | 45.0a | ||||
| Use of DOACs | 26.8 | 5.7 | 28.7a | ||||
Abbreviations: DACH, Austria, Switzerland, and Germany; DOAC, direct oral anticoagulants; DVT, deep vein thrombosis; SD, standard deviation; VKA, vitamin K antagonists; VTE: venous thromboembolism.
a Difference between the groups with/without active cancer reached statically significant level at P < .05.